GlassScriptPhysician profile
Bridgett D Foreman
NPI 1902226285
$5,667.32
in general payments reported to CMS, 2019-2025
31 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $383 · 2021: $667 · 2022: $773 · 2023: $1,118 · 2024: $1,269 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,472.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,021.25 | 2020-2025 | |
| Novo Nordisk INC | $818.26 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $452.99 | 2022-2025 | Auvelity |
| Pfizer INC. | $326.49 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $254.09 | 2019-2024 | Trintellix |
| Amgen INC. | $245.56 | 2019-2025 | Repatha, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $210.04 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $199.94 | 2019-2025 | Mounjaro, Trulicity |
| Otsuka America Pharmaceutical, INC. | $144.33 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $137.90 | 2022-2023 | Arexvy |
| Dexcom, INC. | $79.66 | 2021-2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $77.18 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $75.76 | 2021-2024 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $68.51 | 2022-2025 | Gvoke Hypopen |
| Allergan, INC. | $67.97 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $61.61 | 2023-2024 | Crysvita |
| Arbor Pharmaceuticals, INC. | $51.35 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.87 | 2019-2025 | Xifaxan, Trulance |
| Inari Medical, INC. | $48.05 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sumitomo Pharma America, INC. | $43.15 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $40.84 | 2019-2022 | |
| Sobi, INC | $32.18 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.18 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.78 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $20.12 | 2022 | |
| Ardelyx, INC. | $16.39 | 2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $16.05 | 2023 | |
| Currax Pharmaceuticals LLC | $15.46 | 2024 | Contrave |
| Genentech USA, INC. | $14.51 | 2019 | |
| Sanofi Pasteur INC. | $13.61 | 2025 | |
| Eisai INC. | $13.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridgett Foreman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.